Document is current
Any future updates will be listed below
-
Authors
Drabe, Camilla Heldbjerg https://orcid.org/0000-0002-9053-9047
Laustsen, Mira Marie https://orcid.org/0009-0007-3223-0440
Marquart, Hanne Vibeke https://orcid.org/0000-0001-9740-6522
Hartling, Hans Jakob https://orcid.org/0000-0002-4886-0419
Marvig, Rasmus L. https://orcid.org/0000-0002-5267-3173
Helweg-Larsen, Jannik https://orcid.org/0000-0001-7192-0144
Hansen, Ann-Brit Eg https://orcid.org/0000-0003-4228-3822
Lundgren, Jens https://orcid.org/0000-0001-8901-7850
Helleberg, Marie https://orcid.org/0000-0002-2370-1657
Borgwardt, Line https://orcid.org/0000-0003-1719-9856
Katzenstein, Terese L. https://orcid.org/0000-0002-2233-500X
-
Funding
Funding for this research was provided by:
National Hospital
- License Information
-
More Information
Article History
Received: 29 November 2024
Accepted: 24 May 2025
First Online: 2 June 2025
Change Date: 9 July 2025
Change Type: Update
Change Details: The original version of this paper has been updated to reflect a change in the license subtype from CC BY-NC-ND to CC BY.
Declarations
:
: The study was performed according to the principles of the Declaration of Helsinki and approved by the Danish Regional Ethics Committee (H-15009663). All participants provided written informed consent.
: CD: travel grant and speakers fee from Takeda Pharma. MH: speakers fee from AstraZeneca, Gilead, Sanofi, GSK and Leo Pharma and a research grant from AstraZeneca. LGB: consultant and speakers fee from Chiesi Farmaceutici S.p.A. AEH: travel grants and speakers fees from CSL Behring and travel grants from Takeda Pharma. TLK: personal fees and grants, including travel grants, from ViiV/Glaxo Smith Kline, Gilead, Merck Sharp & Dohme, CLS Behring, Takeda, Chiesi and Vertex. All unrelated to the current study.
